In cirrhotic patients with gastrointestinal bleeding, antibiotic prophylaxis decreases the incidence of infections but most randomized trials have not shown an increase in survival. The aim of this meta-analysis was to assess the efficacy of antibiotic prophylaxis in the prevention of infections and
Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study
✍ Scribed by Gaetanǒ Idéo; Giorgio Bellati; Edoardo Fesce; Daniela Grimoldi
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 495 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
Propranolol has been reported to prevent the risk of hemorrhage in patients who survived episodes of variceal rupture. Since the first bleeding episode can be lethal, we did a prospective, randomized trial to see whether P-blockers could also prevent the first hemorrhage. Seventy-nine consecutive cirrhotics with large esophageal varices by endoscopy and who had never bled were randomly allocated to one of the following treatments: placebo; ranitidine (300 mg per day), or nadolol (40 to 120 mg per day)-which is not cardioselective, reduces portal hypertension and does not interfere with renal flow. Since no significant differences between ranitidine and placebo treatment were observed, the two groups were combined as the control group and compared with the nadolol group.
After a mean follow-up of 2 4 months, only 1 of the 30 patients in the nadolol group had bled, while 11 of the 49 patients in the control group had bled. The percentages of patients who had not bled 1 and 2 years after the inclusion were 100 and 94.4% for the nadolol group and 81.2 and 70.2% for the control group (p < 0.02), respectively. There were no differences in the mortality rate.
In conclusion, nadolol significantly protects against the first gastrointestinal bleeding episode in cirrhotics.
Propranolol has been found to decrease portal hypertension and t o reduce the incidence of rebleeding from ruptured esophageal varices in patients with well-compensated alcoholic cirrhosis (1, 2). Variceal bleeding is a threatening event with a high mortality rate from 28 t o 80% (3-7). To see whether P-blockers could also prevent the initial hemorrhage, in 1982 we started a prospective, randomized, single-blind trial comparing nadolol with ranitidine and placebo. Nadolol was chosen since it is not cardioselective, is not extensively metabolized in the liver, does not interfere with renal flow and greatly reduces portal hypertension (8)(9)(10)(11). Ranitidine, which inhibits gastric acid secretion and increases lower esophageal sphincter pressure (12), was initially tested because of the claims t h a t peptic acid reflux may play some role
📜 SIMILAR VOLUMES
Predictive criteria for a first variceal hemorrhage lack substantial accuracy. Cross-sectional studies suggest a close relationship between variceal pressure (VP) and the occurrence of variceal bleeding. In the present prospective cohort study, the significance of VP measurement for prediction of a
We have previously reported the results of a controlled trial showing that continuous oral administration of propranolol reduced the risk of recurrent gastrointestinal bleeding in patients with cirrhosis; only part of our patients had been followed for 1 year. This controlled trial was continued for
In a previous randomized trial, we demonstrated that propranolol prevented recurrent gastrointestinal bleeding in patients with cirrhosis. We have undertaken the present study in a new group of patients to ascertain the factors associated with rebleeding. Among 232 patients with cirrhosis admitted f
We conducted a prospective, multicenter, randomized trial to compare the efficacy of sclerotherapy plus propranolol with that of propranolol alone in the prevention of recurrent gastroesophageal bleeding in severely cirrhotic patients. For 2 yr (1987 to 1988) 131 patients (96% of whom were alcoholic